[iNOVA4Health Seminar] Re-Generando: Gene modified dendritic cells and CAR-T cells to rebuild the immune system
Renata Stripecke
| When |
08 Oct, 2019
from
02:00 pm to 03:00 pm |
|---|---|
| Where | Auditorium ITQB NOVA |
| Contact Name | Paula Alves |
| Add event to your calendar |
iCal
|
iNOVA4Health Seminar
Title: Re-Generando: Gene modified dendritic cells and CAR-T cells to rebuild the immune system
Speaker: Renata Stripecke
Affiliation: Associate Professor and Head of Unit Regenerative Immune Therapies Applied, Hannover Medical School
Host: Paula Alves
Short CV
Renata Stripecke is Associate Professor at Hannover Medical School – Department of Hematology Hemostasis, Oncology and Stem Cell Transplantation and Principal Investigator at the German Center for Infections Research. Renata’s research interests include the development and validation of innovative reprogrammed cellular vaccines and CAR-T cells for de novo reconstitution of adaptive immune responses in cancer and chronic infections. With over 60 published research papers, 2 patents and numerous projects, Renata is an active member of several scientific societies such as the American and the European Society of Gene and Cell Therapy.
Abstract
Dr. Stripecke’s research focus is on leukemia relapse and chronic viral infections (HCMV and EBV) that can be devastating for immune compromised patients after stem cell transplantation. Novel genetically modified cells consisting of “induced dendritic cells” for immunization and “CAR-T cells” for adoptive T cell therapy are in development so that immune compromised patients can recover fast, potent and specific de novo immune responses. These activities are advancing towards GMP-compliant protocols to obtain the regulatory approvals for eventual evaluation in first-in-human Phase I safety clinical trials. Efficacy and safety testing of these gene-modified cells are performed in mice transplanted with human hematopoietic stem cells and reconstituting a human immune system (“humanized mice”). This complex human-mouse hybrid system is further being used to study human T and B cell responses in different tissues using “big data” approaches for identification of immunological signatures of responses to immune therapeutic interventions.
